Panto time – look out Mother, it’s right in front of your eyes!
With growing pressure on clinical decisions, you, like many others in clinical practice, have probably thought the last few years were quite tough. But for the industry, haemophilia has proven something of a golden egg.
According to a new report by analysts at TechNavio, the global haemophilia market grew at a compound annual growth rate of 6.07% over the period 2013-2018. Sadly, TechNavio’s press release doesn’t give the actual size of the market – and at £1600 Haemnet doesn’t quite have the resources to buy a copy. But a year ago analysts were suggesting it was worth $8.5 billion in 2011 (http://corporate.morningstar.com/us/html/pdf/Healthcare-Observer-Jan-2013.pdf).
This will be the same haemophilia market in which 75% of people with a bleeding disorder do not receive adequate care – or any care at all.
The TechNavio report covers the Americas, and the EMEA and APAC regions and is based on “inputs from industry experts”. The listing of key players in the market is a little out of date (Inspiration Biopharmaceuticals?) but no doubt those companies that part with £2240 for a corporate license will be pleased with their investment.
For the report offers such companies some important insights. While acknowledging there have been some major innovations in haemophilia, TechNavio (or at least their press release!) cautions that, “the high cost of haemophilia therapeutics could pose a challenge to the growth of this market.”
In other words, “price it too highly and no-one will buy”. Or, perhaps, don’t kill the goose that laid that golden egg.
Have you seen the price of old rope these days?